[go: up one dir, main page]

WO2009035955A1 - Procédés de détection d'enterobacter sakazakii - Google Patents

Procédés de détection d'enterobacter sakazakii Download PDF

Info

Publication number
WO2009035955A1
WO2009035955A1 PCT/US2008/075663 US2008075663W WO2009035955A1 WO 2009035955 A1 WO2009035955 A1 WO 2009035955A1 US 2008075663 W US2008075663 W US 2008075663W WO 2009035955 A1 WO2009035955 A1 WO 2009035955A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
polynucleotide
primer
biological sample
identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/075663
Other languages
English (en)
Inventor
Christine Marie Sadek
Ian Garthwaite
Philip Albert Myers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Innovative Properties Co
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Publication of WO2009035955A1 publication Critical patent/WO2009035955A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • Enterobacter sakazakii is a bacterium belonging to the family Enterobacteriaceae, which contains a number of bacterial species that are commonly found among the intestinal flora in humans and animals and may be found in the environment.
  • the World Health Organization has reported that E. sakazakii has been implicated in outbreaks causing meningitis or enteritis, some of which have resulted in particularly high mortality among infants that were infected with the organism.
  • the infections can also result in severe, lasting complications that may include neurological disorders.
  • E. sakazakii has been detected in other types of food
  • powdered infant formula has been linked specifically to outbreaks of disease.
  • the organism can enter the powdered infant formula during production and is capable of surviving process and storage conditions. Additionally, the organisms can be introduced into the infant formula as it is being reconstituted by the user.
  • E. sakazakii was described as a bacterial species in 1980. It was formerly known as yellow pigmented Enterobacter cloacae. As reported by Leuschner, Baird, Donald and Cox in "A Medium for the Presumptive Detection of E. sakazakii in Infant Formula," Food Microbiology 21 (2004), 527-533, E. sakazakii has been implicated in a severe form of neonatal meningitis with a high mortality rate. It is reported that many newborns with E. sakazakii meningitis die within days of infection, and that the case- fatality rates vary between 40 and 80%, Nazarowec-White and Farber, "E.
  • nucleic acid-based detection method there is a need for a nucleic acid-based detection method to provide a more rapid, specific and sensitive test than the traditional culture methods.
  • the present invention includes methods for detecting E. sakazakii in a biological sample.
  • the method may include amplifying a target polynucleotide present in a biological sample to result in an amplified product, wherein the target polynucleotide is associated with Enterobacter sakazakii.
  • the target polynucleotide may be a mms polynucleotide from the mms
  • primers that can be used to amplify such a polynucleotide include, for instance, a first primer that includes a nucleotide sequence with at least about 80% identity to SEQ ID NO:1, and a second primer that includes a nucleotide sequence with at least about 80% identity to SEQ ID NO:2, wherein the primer pair amplifies nucleotides 186-235 of SEQ ID NO:3.
  • the methods may include amplifying a target polynucleotide present in a biological sample to result in an amplified product, wherein the biological sample is contacted with a first mms primer and a second mms primer under suitable conditions to result in an amplified product.
  • the first mms primer may include a nucleotide sequence with at least about 80% identity to SEQ ID NO:1
  • the second mms primer may include a nucleotide sequence with at least about 80% identity to SEQ ID NO:2, wherein the primer pair amplifies nucleotides 186 - 235 of SEQ ID NO:3.
  • the amplified product is detected, wherein the presence of the amplified product is indicative of the presence of E. sakazakii in the biological sample.
  • the methods may include contacting a biological sample with a first mms primer and a second mms primer to form a mixture.
  • the first mms primer may include a nucleotide sequence with at least about 80% identity to SEQ ID NO:1
  • the second mms primer may include a nucleotide sequence with at least about 80% identity to SEQ ID NO:2, wherein the primer pair amplifies nucleotides 186 - 235 of SEQ ID NO:3.
  • the mixture is exposed to conditions suitable to form an amplified product if a mms polynucleotide is present in the biological sample, and the absence of the amplified product is detected, wherein the absence of the amplified product is indicative of the absence of E. sakazakii the biological sample.
  • the methods of the present invention may further include obtaining a biological sample.
  • the biological sample may be from an individual suspected of infection with E. sakazakii, and the biological sample may be obtained from fecal material.
  • the biological sample may be obtained from a food or a beverage for consumption or from a raw material that is used to produce food or beverages for consumption.
  • the biological sample may come from a food processing environment, food processing equipment, or from containers that are used for temporary storage of food or beverages or to store materials used to make food or beverages.
  • the detecting of the presence or absence of an amplified product may be performed after each cycling step.
  • the present invention also provides methods for isolating a polynucleotide.
  • the methods may include providing a mixture of single stranded polynucleotides, exposing the mixture to an oligonucleotide under conditions suitable for specific hybridization of the oligonucleotide to a single stranded polynucleotide to result in a hybrid.
  • the oligonucleotide includes a nucleotide sequence selected from one having at least about 80% identity to SEQ ID NO: 1, at least about 80% identity to SEQ ID NO:2. The hybrid may then be washed to remove contaminants.
  • the oligonucleotide may include an affinity label, and the oligonucleotide may be attached to a solid phase material before or after the exposing.
  • the mixture may be obtained from a biological sample, and the method can further include denaturing the polynucleotides present in the biological sample to result in single stranded polynucleotides.
  • kits can include packaging materials, a first mms primer, a second mms primer.
  • the first primer may include a nucleotide sequence with at least about 80% identity to SEQ ID NO:1 and the second primer may include a nucleotide sequence with at least about 80% identity to SEQ ID NO:2, wherein the primer pair amplifies nucleotides 186 - 235 of SEQ ID NO:3.
  • the present invention includes an isolated polynucleotide wherein the polynucleotide is a product of DNA amplification and wherein the polynucleotide is about 50 base pairs in length.
  • the 50 base pair polynucleotide may have at least about 80% identity to SEQ ID NO:3.
  • the present invention includes an isolated first polynucleotide wherein the first polynucleotide comprises a nucleotide sequence with at least about 80% identity to SEQ ID NO:1, wherein the first polynucleotide amplifies a second polynucleotide comprising nucleotides 186 - 235 of SEQ ID NO:3 when used with SEQ ID NO:2.
  • the present invention includes an isolated first polynucleotide wherein the first polynucleotide comprises a nucleotide sequence with at least about 80% identity to SEQ ID NO:2, wherein the first polynucleotide amplifies a second polynucleotide comprising nucleotides 186 - 235 of SEQ ID NO:3 when used with SEQ ID NO:2.
  • the present invention includes a solid support comprising an amplified polynucleotide with at least about 80% identity to nucleotides 186 - 235 of SEQ ID NO:3.
  • polynucleotide refers to a polymeric form of nucleotides of any length, either ribonucleotides, deoxynucleotides, or peptide nucleic acids (PNA), and includes both double- and single-stranded RNA, DNA, and PNA.
  • a polynucleotide may include nucleotide sequences having different functions, including for instance coding regions, and non-coding regions such as regulatory regions.
  • a polynucleotide can be obtained directly from a natural source, or can be prepared with the aid of recombinant, enzymatic, or chemical techniques.
  • a polynucleotide can be linear or circular in topology.
  • a polynucleotide can be, for example, a portion of a vector, such as an expression or cloning vector, or a fragment.
  • An "oligonucleotide” refers to a polynucleotide of the present invention, typically a primer and/or a probe.
  • a “target polynucleotide,” as used herein, contains a polynucleotide sequence of interest, for which amplification is desired.
  • the target sequence may be known or not known, in terms of its actual sequence.
  • a “coding region” is a nucleotide sequence that encodes a polypeptide and, when placed under the control of appropriate regulatory sequences expresses the encoded polypeptide. The boundaries of a coding region are generally determined by a translation start codon at its 5' end and a translation stop codon at its 3' end.
  • a “regulatory sequence” is a nucleotide sequence that regulates expression of a coding sequence to which it is operably linked.
  • Nonlimiting examples of regulatory sequences include promoters, enhancers, transcription initiation sites, translation start sites, translation stop sites, and transcription terminators.
  • operably linked refers to a juxtaposition of components such that they are in a relationship permitting them to function in their intended manner.
  • a regulatory sequence is "operably linked" to a coding region when it is joined in such a way that expression of the coding region is achieved under conditions compatible with the regulatory sequence.
  • Primer is an oligonucleotide that is complementary to at least a portion of target polynucleotide and, after hybridization to the target polynucleotide, may serve as a starting-point for an amplification reaction and the synthesis of an amplification product.
  • a “primer pair” refers to two primers that can be used together for an amplification reaction
  • mms primers refers to a primer pair that hybridizes to mms polynucleotides, and can initiate amplification under the appropriate conditions.
  • complement and “complementary” as used herein, refer to the ability of two single stranded polynucleotides (for instance, a primer and a target polynucleotide) to base pair with each other, where an adenine on one strand of a polynucleotide will base pair to a thymine or uracil on a strand of a second polynucleotide and a cytosine on one strand of a polynucleotide will base pair to a guanine on a strand of a second polynucleotide.
  • Two polynucleotides are complementary to each other when a nucleotide sequence in one polynucleotide can base pair with a nucleotide sequence in a second polynucleotide.
  • 5'- ATGC and 5'-GCAT are complementary.
  • the terms "substantial complement” and “substantially complementary” as used herein, refer to a polynucleotide that is capable of selectively hybridizing to a specified polynucleotide under stringent hybridization conditions. Stringent hybridization can take place under a number of pH, salt and temperature conditions. The pH can vary from 6 to 9, preferably 6.8 to 8.5.
  • the salt concentration can vary from 0.15 M sodium to 0.9 M sodium, and other cations can be used as long as the ionic strength is equivalent to that specified for sodium.
  • the temperature of the hybridization reaction can vary from 30 0 C to 80 0 C, preferably between 45°C and 70 0 C. Additionally, other compounds can be added to a hybridization reaction to promote specific hybridization at lower temperatures, such as at or approaching room temperature. Among the compounds contemplated for lowering the temperature requirements is formamide.
  • a polynucleotide is typically "substantially complementary" to a second polynucleotide if hybridization occurs between the polynucleotide and the second polynucleotide.
  • specific hybridization refers to hybridization between two polynucleotides under stringent hybridization conditions.
  • Identity refers to sequence similarity between an oligonucleotide, such as a primer, and at least a portion of a target polynucleotide or an amplification product.
  • the similarity is determined by aligning the residues of the two polynucleotides (i.e., the nucleotide sequence of a primer and a reference nucleotide sequence) to optimize the number of identical nucleotides along the lengths of their sequences; gaps in either or both sequences are permitted in making the alignment in order to optimize the number of shared nucleotides, although the nucleotides in each sequence must nonetheless remain in their proper order.
  • the sequence similarity is typically at least about 80% identity, at least about 85% identity, at least about 90% identity, or at least about 95% identity.
  • Sequence similarity may be determined, for example, using sequence techniques such as GCG FastA (Genetics Computer Group, Madison, Wisconsin), MacVector 4.5 (Kodak/IBI software package) or other suitable sequencing programs or methods known in the art.
  • sequence similarity between a primer and a target polynucleotide, or between a probe and an amplification product is determined using the Blastn program of the BLAST 2 search algorithm, as described by Tatusova, et al. (FEMS Microbiol Lett 1999, 174:247-250), and available through the World Wide Web, for instance at the internet site maintained by the National Center for Biotechnology Information, National Institutes of Health.
  • identity is referred to as "identities.”
  • a “label” refers to a moiety attached (covalently or non-covalently), or capable of being attached, to an oligonucleotide, which provides or is capable of providing information about the oligonucleotide (e.g., descriptive or identifying information about the oligonucleotide) or another polynucleotide with which the labeled oligonucleotide interacts (e.g., hybridizes). Labels can be used to provide a detectable (and optionally quantifiable) signal. Labels can also be used to attach an oligonucleotide to a surface.
  • a “fluorophore” is a moiety that can emit light of a particular wavelength following absorbance of light of shorter wavelength.
  • the wavelength of the light emitted by a particular fluorophore is characteristic of that fluorophore.
  • a particular fluorophore can be detected by detecting light of an appropriate wavelength following excitation of the fluorophore with light of shorter wavelength.
  • the term "quencher” as used herein refers to a moiety that absorbs energy emitted from a fluorophore, or otherwise interferes with the ability of the fluorescent dye to emit light.
  • a quencher can re-emit the energy absorbed from a fluorophore in a signal characteristic for that quencher, and thus a quencher can also act as a fluorophore (a fluorescent quencher). This phenomenon is generally known as fluorescent resonance energy transfer (FRET).
  • FRET fluorescent resonance energy transfer
  • a quencher can dissipate the energy absorbed from a fluorophore as heat (a non-fluorescent quencher).
  • a “biological sample” refers to a sample obtained from eukaryotic or prokaryotic sources.
  • eukaryotic sources include mammals, such as a human (e.g. a patient).
  • prokaryotic sources include bacteria, such as E. sakazakii.
  • the biological sample can be, for instance, in the form of a single cell, in the form of a tissue, or in the form of a fluid. Cells or tissue can be derived from in vitro culture.
  • Biological samples also include samples of food, food ingredients, food residue, beverages, beverage ingredients, or beverage residue, samples from process equipment, and water (e.g., potable water or process water).
  • Conditions that "allow” an event to occur or conditions that are “suitable” for an event to occur are conditions that do not prevent such events from occurring. Thus, these conditions permit, enhance, facilitate, and/or are conducive to the event.
  • Such conditions known in the art and described herein, may depend upon, for example, the nature of the nucleotide sequence, temperature, and buffer conditions. These conditions may also depend on what event is desired, such as hybridization, cleavage, strand extension or transcription.
  • An “isolated” polynucleotide refers to a polynucleotide that has been removed from its natural environment.
  • a “purified” polynucleotide is one that is at least about 60% free, preferably at least about 75% free, and most preferably at least about 90% free from other components with which they are naturally associated.
  • the words "preferred” and “preferably” refer to embodiments of the invention that may afford certain benefits, under certain circumstances. However, other embodiments may also be preferred, under the same or other circumstances. Furthermore, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful, and is not intended to exclude other embodiments from the scope of the invention.
  • the present invention includes methods for detecting polynucleotides that are characteristic of a target nucleic acid sequence, such as a target nucleic acid sequence from E. sakazakii. For instance, the present invention includes methods directed to detecting a portion of a mms coding region present in E. sakazakii using amplification techniques and oligonucleotides, such as primers and probes. Using the methods of the present invention, it is possible to identify the presence of E. sakazakii in a biological sample.
  • the present invention also includes the oligonucleotides described herein.
  • the present invention also includes amplifying and detecting small (e.g., about 50 base pair) oligonucleotide sequences. The amplification of such small target nucleotide sequences affords the advantage of very short periods for primer extension during the polymerase chain reaction (PCR) assays, thus enabling a faster assay.
  • PCR polymerase chain reaction
  • Oligonucleotides of the present invention include primers that can be used to amplify a portion of a mms coding region.
  • the oligonucleotides may be used in a simple elongation reaction, when mixed with a solution containing an appropriate buffer, polymerase enzyme, and deoxyribonucleotide triphosphates and annealed to a suitable complementary template.
  • An example of a mms coding region is disclosed at SEQ ID NO:3 (Genbank accession number LO 1755).
  • Primers useful for amplifying a portion of a mms coding region may amplify a region of SEQ ID NO:3, preferably a region that includes nucleotides from about 186 to about 235 of SEQ ID NO:3. Accordingly, the nucleotide sequence of a primer may correspond to nucleotides from about 186 to about 208, preferably nucleotides 186 to 208 (referred to herein as SEQ ID NO: 1). Likewise, the nucleotide sequence of a primer may correspond to the complement of nucleotides from about 211 to about 235, preferably 211 to 235
  • primer pairs useful to amplify a portion of a mms coding region include, but are not limited to, the following: SEQ ID NO:1 and SEQ ID NO:2; a primer having sequence similarity to SEQ ID NO:1 and SEQ ID NO:2; SEQ ID NO:1 and a primer having sequence similarity to SEQ ID NO:2; and a primer having sequence similarity to SEQ ID NO: 1 and a primer having sequence similarity to SEQ ID NO:2.
  • primers for PCR amplification are about 20-25 nucleotides in length and amplify a polynucleotide of about 100-150 nucleotides or more in length.
  • the proximal terminal nucleotides of the inventive primers of the present disclosure are separated by a very short distance (e.g. 2 nucleotides).
  • the primers of SEQ ID NO:1 and SEQ ID NO:2 were selected to be in close proximity to one another in order to minimize the time necessary for primer extension in a PCR assay.
  • Primers that amplify a mms coding region can be designed using readily available computer programs, such as Primer Express® (Applied Biosystems, Foster City, CA), and IDT® OligoAnalyzer 3.0 (Integrated DNA Technologies, Coralville, IA).
  • Factors that can be considered in designing primers include, but are not limited to, melting temperatures, primer length, size of the amplification product, and specificity.
  • Primers useful in the amplification methods described herein typically have a melting temperature (T M ) that is greater than at least 56°C, at least 57°C, at least 58°C, or at least 59°C.
  • T M melting temperature
  • the T M of a primer can be approximated by the Wallace Rule (Wallace et al, 1979, Nucleic Acids Res., 6:3543-3557) or by using a computer program, such as IDT Oligo Analyzer 3.0.
  • the primers of a primer pair will have T M S that vary by no greater than 4°C, no greater than 3°C, no greater than 2°C, or no greater than 1 0 C.
  • two primers are long enough to hybridize to the target polynucleotide and not hybridize to other non-target polynucleotides present in microbes, preferably, other members of the family Enterobacteriaceae, other species of Enterobacter, and other polynucleotides that may be present in the amplification reaction.
  • Primer length is generally between about 15 and about 30 nucleotides (for instance, 15, 16, 18, 20, 22, 24, 26, 28, or 30 nucleotides).
  • a primer useful in the present invention may have sequence similarity to SEQ ID NO: 1 and SEQ ID NO:2.
  • Non-complementary nucleotides in such a primer with sequence similarity can be located essentially anywhere throughout the primer.
  • the first nucleotide at the 3' end of a primer with sequence similarity is identical to the corresponding first nucleotide in SEQ ID NO:1 and SEQ ID NO:2.
  • a primer having sequence similarity to SEQ ID NO:1 and SEQ ID NO:2 has the activity of amplifying a target polynucleotide under the appropriate conditions.
  • a candidate primer i.e., a primer being compared to SEQ ID NO:1 or SEQ ID NO:2
  • having sequence similarity has the activity of amplifying a target polynucleotide
  • a Mastercycler Personal Eppendorf, Germany
  • thermal cycler with the following profile: 94°C for 4 minutes, then 40 cycles of 94°C for 20 seconds, 58°C for 20 seconds, and 72 degrees for 60 seconds.
  • a final extension step e.g., for up to several minutes at 72 degrees
  • the target polynucleotide for evaluating a candidate primer having sequence similarity to either SEQ ID NO:1 or SEQ ID NO:2 is one that includes nucleotides 186 to 235 of SEQ ID NO:3. Such a nucleotide sequence is present in whole cell DNA obtained from the E. sakazakii designated Tecra International Culture Collection strain number 4217.
  • the second primer used is SEQ ID NO:2.
  • the second primer used is SEQ ID NO:1.
  • oligonucleotides of the present invention may be used with appropriate probes that can hybridize to at least a portion of an amplified product that results from the use ofmms primers.
  • probes which may be useful in performing real-time PCR, can be selected according to general principles known in the art for PCR probe selection. Factors that can be considered in designing probes useful in the real-time PCR methods include, but are not limited to, melting temperature, length, location of the probe with respect to the primers. Typically, a probe will have a T M that is greater than the highest T M of the primers with which the probe is to be used.
  • a probe has a T M that is at least 5°C greater, at least 6°C greater, at least 7°C greater, at least 8°C greater, at least 8.5°C greater, at least 9°C greater, or at least 9.5°C greater than the highest T M of the primer pair with which the probe is to be used.
  • the greater Tm permits the probe to hybridize before the primer, which aids in maximizing the labeling of each amplification product with probe.
  • a probe is long enough to hybridize to the target polynucleotide (and the amplification product) and not hybridize to other non-target polynucleotides present in a microbe, and other polynucleotides that may be present in the amplification reaction. Probe lengths are generally between about 15 nucleotides and about 30 nucleotides.
  • a probe and the primers with which the probe is used will not hybridize to the same nucleotides of an amplification product.
  • a probe will hybridize to one strand of an amplified product, and is typically designed to hybridize to the amplified product before the primer that hybridizes to that strand.
  • a probe hybridizes to one strand of an amplified product within no more than 1, 2, 3, 4, or 5 nucleotides of the primer that hybridizes to the same strand.
  • the two probes preferably hybridize to the same strand of an amplified product, and the two probes may optionally hybridize to the same amplification product within 1, 2, 3, 4, or 5 nucleotides of each other.
  • a primer of the present invention may further include additional nucleotides.
  • additional nucleotides are present at the 5' end of the primer, and include, for instance, nucleotides that include a restriction endonuclease site, nucleotides that form a hairpin loop, and other nucleotides that permit the primer to be used as, for instance, a scorpions primer (see, for instance, Whitcombe et al., U.S. Patent 6,326,145, and Whitcombe et al., Nat. BiotechnoL, 1999;17:804-817), an amplifluor primer (see, for instance, Nazarenko et al., Proc. Natl. Acad. Sci.
  • a primer includes such additional nucleotides, the additional nucleotides are not included when determining if the primer has sequence similarity to SEQ ID NO:1 or SEQ ID NO:2. Likewise, the additional nucleotides are not included in determining the length of a primer, which is generally between about 10 and about 50 nucleotides.
  • Oligonucleotides of the present invention include probes that can be used to hybridize to at least a portion of an amplified product that results from the use of mms primers. Such mms probes useful herein hybridize to a region that includes nucleotides from about 186 to about 235 of SEQ ID NO:3, preferably nucleotides 186 to 235 of SEQ ID NO:3. Nucleotides of an oligonucleotide of the present invention may be modified. Such modifications can be useful to increase stability of the polynucleotide in certain environments. Modifications can include a nucleic acid backbone, base, sugar, or any combination thereof. The modifications can be synthetic, naturally occurring, or non- naturally occurring.
  • a polynucleotide of the present invention can include modifications at one or more of the nucleic acids present in the polynucleotide.
  • backbone modifications include, but are not limited to, phosphonoacetates, thiophosphonoacetates, phosphorothioates, phosphorodithioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, and peptide nucleic acids (Nielson et al, U.S. Pat. No. 5,539,082;
  • nucleic acid base modifications include, but are not limited to, inosine, purine, pyridin-4-one, pyridin-2- one, phenyl, pseudouracil, 2,4,6-trimethoxy benzene, 3-methyl uracil, dihydrouridine, naphthyl, aminophenyl, 5-alkylcytidines (e.g., 5-methylcytidine), 5-alkyluridines (e.g., ribothymidine), 5-halouridine (e.g., 5-bromouridine) or 6-azapyrimidines or 6- alkylpyrimidines (e.g.
  • nucleic acid sugar modifications include, but are not limited to, 2'-sugar modification, e.g., T- O-methyl nucleotides, 2'-deoxy-2'-fluoro nucleotides, 2'-deoxy-2'-fluoroarabino, T-O- methoxyethyl nucleotides, 2'-O-trifluoromethyl nucleotides, 2'-O-ethyl- trifluoromethoxy nucleotides, 2'-O-difluoromethoxy-ethoxy nucleotides, or 2'-deoxy nucleotides.
  • 2'-sugar modification e.g., T- O-methyl nucleotides, 2'-deoxy-2'-fluoro nucleotides, 2'-deoxy-2'-fluoroarabino, T-O- methoxyethyl nucleotides, 2'-O-trifluoromethyl nucleotides, 2'-O-
  • Oligonucleotides may include a label.
  • exemplary labels include, but are not limited to, fluorophore labels (including, e.g., quenchers or absorbers), non-fluorescent labels, colorimetric labels, chemiluminescent labels, bioluminescent labels, radioactive labels, mass-modifying groups, affinity labels, magnetic particles, antigens, enzymes
  • Labels may provide signals detectable by fluorescence, radioactivity, colorimetry, gravimetry, X-ray diffraction or absorption, magnetism, enzymatic activity, and the like.
  • Affinity labels provide for a specific interaction with another molecule. Examples of affinity labels include, for instance, biotin, avidin, streptavidin, dinitrophenyl, digoxigenin, cholesterol, polyethyleneoxy, haptens, and peptides.
  • the label may be incorporated into the oligonucleotide by using labeled deoxyribonucleotide triphosphates (dNTP's) when synthesizing the oligonucleotides.
  • dNTP's labeled deoxyribonucleotide triphosphates
  • a label is a fluorophore.
  • Fluorophore labels include, but are not limited to, dyes of the fluorescein family, the carboxyrhodamine family, the cyanine family, and the rhodamine family.
  • Dyes of the fluorescein family include, e.g., 6-carboxyfluorescein (FAM), 2',4',1,4,- tetrachlorofluorescein (TET), 2 > ,4 > ,5',7 > ,l,4-hexachlorofluorescein (HEX), T, T- dimethoxy-4',5'-dichloro-6-carboxyrhodamine (JOE), 2'-chloro-5'-fluoro-7',8'-fused phenyl- 1 ,4-dichloro-6-carboxyfluorescein (NED), 2'-chloro-7'-phenyl- 1 ,4-dichloro-6- carboxyfluorescein (VIC), 6-carboxy-X-rhodamine (ROX), and 2',4',5',7'-tetrachloro-5- carboxy- fluorescein (ZOE). Dyes of the carboxyrh
  • Dyes of the cyanine family include Cy2, Cy3, Cy3.5, Cy5, Cy5.5, and Cy7.
  • Fluorophores are readily available commercially from, for instance, Perkin-Elmer (Foster City, Calif), Molecular Probes, Inc. (Eugene, Oreg.), and Amersham GE Healthcare (Piscataway, N.J.).
  • the label may be a quencher. Quenchers may be fluorescent quenchers or non- fluorescent quenchers.
  • Fluorescent quenchers include, but are not limited to, TAMRA, ROX, DABCYL, DABSYL, cyanine dyes including nitrothiazole blue (NTB), anthraquinone, malachite green, nitrothiazole,and nitroimidazole compounds.
  • exemplary non-fluorescent quenchers that dissipate energy absorbed from a fluorophore include those available under the trade designation BLACK HOLE, from
  • a fluorophore and a quencher are used together, and may be on the same or different oligonucleotides.
  • a fluorophore and fluorescent quencher can be referred to as a donor fluorophore and acceptor fluorophore, respectively.
  • a number of convenient fluorophore/quencher pairs are known in the art (see, for example, Glazer et al, Current Opinion in Biotechnology, 1997;8:94-102; Tyagi et al., Nat. BiotechnoL, 1998;16:49- 53) and are readily available commercially from, for instance, Molecular Probes (Junction City, OR), and Applied Biosystems (Foster City, CA).
  • donor fluorophores that can be used with various acceptor fluorophores include, but are not limited to, fluorescein, Lucifer Yellow, B-phycoerythrin, 9-acridineisothiocyanate, Lucifer Yellow VS, 4-acetamido- 4'-isothio-cyanatostilbene-2,2'-disulfonic acid, 7-diethylamino-3-(4'- isothiocyanatophenyl)-4-methylcoumarin, succinimdyl 1-pyrenebutyrate, and 4- acetamido-4'-isothiocyanatostilbene-2- ,2'-disulfonic acid derivatives.
  • Acceptor fluorophores typically depend upon the donor fluorophore used.
  • acceptor fluorophores include, but are not limited to, LC-Red 640, LC-Red 705, Cy5, Cy5.5, Lissamine rhodamine B sulfonyl chloride, tetramethyl rhodamine isothiocyanate, rhodamine x isothiocyanate, erythrosine isothiocyanate, fluorescein, diethylenetriamine pentaacetate or other chelates of Lanthanide ions (e.g., Europium, or Terbium).
  • Donor and acceptor fluorophores are readily available commercially from, for instance, Molecular Probes or Sigma Chemical Co. (St. Louis, MO).
  • probes useful in real-time assays using donor and acceptor fluorophores include, but are not limited to, adjacent probes (Cardullo et al., Proc. Natl. Acad. Sci. USA, 1988;85:8790- 8794; Wittwer BioTechniques, 1997;22:130- 131), and Taqman probes (Holland et al., Proc. Natl. Acad. Sci. USA, 1991;88:7276- 7280; Livak et al., PCR Methods Appl 1995;4:357-62).
  • probes and primers useful in real-time assays using fluorphores and non- fluorescent quenchers include, but are not limited to, molecular beacons (Tyagi et al., Nat. BiotechnoL, 1996;14:303-308; Johansson et al., J. Am. Chem. Soc, 2002; 124:6950-6956), scorpion primers
  • duplex scorpion primers including duplex scorpion primers
  • amplifluor primers including duplex scorpion primers
  • light-up probes including duplex scorpion primers
  • Polynucleotides of the present invention may be used as probes in a real-time assay wherein one polynucleotide is labelled with a fluorophore, the other polynucleotide is labelled with a fluorescent quencher, and, when both are hybridized to a target polynucleotide, the fluorophore and fluorescent quencher are separated by about 1-5 nucleotide bases.
  • a polynucleotide of the present invention can be present in a vector.
  • a vector is a replicating polynucleotide, such as a plasmid, phage, or cosmid, to which another polynucleotide may be attached so as to bring about the replication of the attached polynucleotide.
  • Construction of vectors containing a polynucleotide of the invention employs standard ligation techniques known in the art. See, e.g., Sambrook et al,
  • a vector can provide for further cloning (amplification of the polynucleotide), i.e., a cloning vector, or for expression of the polynucleotide, i.e., an expression vector.
  • the term vector includes, but is not limited to, plasmid vectors and viral vectors.
  • viral vectors include, for instance, adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, retroviral vectors, and herpes virus vectors.
  • a vector is capable of replication in a bacterial host, for instance E. coli.
  • the vector is a plasmid.
  • Vectors may also include a mms coding region, such as SEQ ID NO:3, or a portion thereof, preferably nucleotides from about 186 to about 235 of SEQ ID NO:3. Such vectors can be used as, for instance, control target polynucleotides.
  • Suitable host cells for cloning or expressing the vectors herein are prokaryotic cells.
  • Suitable prokaryotic cells include eubacteria, such as gram-negative microbes, for example, E. coli.
  • Vectors can be introduced into a host cell using methods that are known and used routinely by the skilled person. For example, calcium phosphate precipitation, electroporation, heat shock, lipofection, microinjection, and viral- mediated nucleic acid transfer are common methods for introducing nucleic acids into host cells.
  • naked DNA can be delivered directly to cells.
  • Polynucleotides of the present invention can be produced in vitro or in vivo.
  • methods for in vitro synthesis include, but are not limited to, chemical synthesis with a conventional DNA/RNA synthesizer. Commercial suppliers of synthetic polynucleotides and reagents for such synthesis are well known. Methods for in vitro synthesis also include, for instance, in vitro transcription using a circular or linear expression vector in a cell free system. Expression vectors can also be used to produce a polynucleotide of the present invention in a cell, and the polynucleotide then isolated from the cell. Methods of use
  • the present invention includes methods for detecting polynucleotides that are characteristic of E. sakazakii. If the sample is obtained from a subject, the method may be used to determine whether the subject is infected with E. sakazakii.
  • the methods of this aspect of the present invention typically include contacting a target polynucleotide with a primer pair of the present invention, amplifying the polynucleotide, and detecting the resulting amplified product.
  • the target polynucleotide used in the methods may be present in a sample.
  • the sample can be a food sample, a beverage sample, a fermentation broth, a forensic sample, an agricultural sample (e.g., from a plant or animal), or an environmental sample (e.g., soil, dirt, garbage, sewage, or water).
  • the sample is a biological sample.
  • a "biological sample” refers to a sample obtained from eukaryotic or prokaryotic sources. Examples of eukaryotic sources include mammals, such as a human or a member of the family Muridae (a murine animal such as rat or mouse). Examples of prokaryotic sources include E. sakazakii or other microbes containing an endogenous or recombinant mms polynucleotide sequence.
  • the biological sample can be, for instance, in the form of a single cell, in the form of a tissue, or in the form of a fluid.
  • Cells or tissue can be derived from in vitro culture.
  • the biological sample can be obtained from, for instance, anal swabs, perirectal swabs, stool samples, blood, and/or body fluids.
  • the biological sample is obtained from a subject suspected of having an Enterobacter infection.
  • a sample may be an isolated polynucleotide, for instance, a polynucleotide present in a vector as described herein, or an polynucleotide isolated using methods described hereinbelow.
  • the sample can be a colony of microorganisms, such as a colony obtained from the surface of an agar plate or a colony obtained from a culture device sold by 3M Company (St. Paul, MN, USA) under the trade name PETRIFILM.
  • the colony may be an axenic culture, or it may be a mixed colony of microorganisms.
  • the sample can be obtained from a broth culture of microorganisms, which may be a monoculture or a mixed culture, as in an enrichment culture.
  • the sample can be a solid sample (e.g., solid tissue) that is dissolved or dispersed in water or an organic medium, or from which the polynucleotide has been extracted into water or an organic medium.
  • the sample can be an organ homogenate.
  • the sample can include previously extracted polynucleotides.
  • the sample may be incubated with an enrichment broth to enrich for E. sakazakii microorganisms that are present.
  • the sensitivity of detection of such a microbe in a sample can be enhanced by including the enrichment culture process prior to sample preparation to extract the polynucleotides for amplification and detection.
  • Sample material e.g., a biological sample is used to inoculate a suitable medium/broth.
  • the broth can provide simple nutrient requirements to promote the growth of the target organism, or may be used to provide selective enrichment, using media supplemented with selective agents, such as antibiotics, at a certain concentration which kills other microbes in the sample but allows for proliferation of E sakazakii, and then the culture is incubated at a suitable temperature (e.g., 37°C) for a period of time (e.g., between 4 and 48 hours; preferably, between 4-24 hours).
  • a suitable temperature e.g., 37°C
  • a period of time e.g., between 4 and 48 hours; preferably, between 4-24 hours.
  • the sample with the microbe of interest is collected from a portion of the culture by centrifugation, filtration, sampling by pipette, or other suitable methods, and then used in methods of the present invention involving amplification and detection.
  • the polynucleotides may be from an impure, partially pure, or a pure sample.
  • the purity of the original sample is not critical, as polynucleotides may be obtained from even grossly impure samples.
  • polynucleotides may be obtained from an impure sample of a biological fluid such as blood, saliva, feces, or tissue. If a sample of higher purity is desired, the sample may be treated according to any conventional means known to those of skill in the art prior to undergoing the methods of the present invention.
  • a polynucleotide may be isolated using methods described hereinbelow.
  • Complex biological samples may contain solid debris and/or amplification inhibitors.
  • Solid debris is commonly removed by sedimentation or centrifugation (separate supernatant from solids), filtration, etc.
  • Amplification inhibitors are often removed by treatment with protein denaturants or proteases, dilution, etc.
  • Undesired polynucleotide-containing cells may be reduced by selective lysis, differential centrifugation, filtration, etc.
  • Specific microbes preferably, species from the Enterobacteriaceae family or Enterobacter genus, may be concentrated or enriched from a sample prior to amplif ⁇ cation of a target polynucleotide to detect the presence of E. sakazakii.
  • a biological sample can be exposed to a matrix functionalized with an agent that will interact with E. sakazakii, but not interact with other components present in a biological sample.
  • the interaction is a reversible retention via a wide variety of mechanisms, including weak forces such as Van der Waals interactions, electrostatic interactions, affinity binding, or physical trapping.
  • useful agents include, but are not limited to, specific interactions, such as those mediated by an anti- Enterobacteriaceae antibody, and non-specific interactions.
  • agents that can be used to mediate non-specific interactions with the Enterobacteriaceae family include silica, zirconia, alumina beads, metal colloids such as gold, and gold coated sheets that have been functionalized through mercapto chemistry, for example (Parthasarathy, U.S. Provisional Application Serial Number 60/913,813, filed April 25, 2007, Attorney Docket No. 62470US002).
  • Agents that interact with E. sakazakii can be present on any solid phase material.
  • solid phase material examples include polyolefin, polystyrene, nylon, poly(meth)acrylate, polyacrylamide, polysaccharide, and fluorinated polymers, as well as resins such as agarose, latex, cellulose, and dextran.
  • the solid material may be in any form, preferably in the form of particulate material (e.g., particles, beads, microbeads, microspheres) or any other form (e.g., fibrils) that can be introduced into a micro fluidic device (Parthasarathy, U.S. Provisional Application Serial Number 60/913,813, filed
  • Polynucleotides present in a sample may be introduced directly into the amplification reaction. Prior to use in an amplification reaction, polynucleotides present in a sample, such as a biological sample, may be prepared for amplification. Treatments for preparing polynucleotides for amplification are well known in the art and used routinely. Polynucleotides can be extracted from a biological sample. Extraction typically includes lysis of microorganisms to release polynucleotides. Lysis herein is the physical disruption of the membranes of the cells. Extraction can be accomplished by the use of standard techniques and reagents.
  • Polynucleotides can be prepared by use of particles, such as magnetic glass particles, under conditions to bind the polynucleotides, followed by washing to remove impurities, and then obtaining purified polynucleotides with a wash designed to remove the bound polynucleotides (MagNA Pure, International Publication No. WO 01/37291 Al).
  • the polynucleotides used as targets in the methods of the present invention may be of any molecular weight and in single-stranded form, double-stranded form, circular, plasmid, etc.
  • Various types of polynucleotides can be separated from each other (e.g., RNA from DNA, or double-stranded DNA from single-stranded DNA).
  • polynucleotides of at least about 100 bases in length, longer molecules of 1000 bases to 10,000 bases in length, and even high molecular weight nucleic acids of up to about 3.2 megabases can be used in the methods of the present invention.
  • Polynucleotide amplification such as the polymerase chain reaction (PCR) is a method for the enzymatic amplification of specific segments of polynucleotides.
  • the amplification is based on repeated cycles of the following basic steps: denaturation of double-stranded polynucleotides, followed by primer annealing to the target polynucleotide, and primer extension by a polymerase (Mullis et al., U.S. Patent
  • the primers are designed to anneal to opposite strands of the DNA, and are positioned so that the polymerase-catalyzed extension product of one primer can serve as the template strand for the other primer.
  • the amplification process can result in the exponential increase of discrete polynucleotide fragments whose length is defined by the 5' ends of the primer pairs.
  • a typical cycling step used in DNA amplification involves two target temperatures to result in denaturation, annealing, and extension.
  • the first temperature is an increase to a predetermined target denaturation temperature high enough to separate the double-stranded target polynucleotide into single strands.
  • the target denaturation temperature of a cycling step is approximately 92°C to 98°C, such as 94°C to 96°C, and the reaction is held at this temperature for a time period ranging between 0 seconds to 5 minutes.
  • the temperature of the reaction mixture is then lowered to a second target temperature.
  • This second target temperature allows the primers (and probe(s), if present) to anneal or hybridize to the single strands of DNA, and promote the synthesis of extension products by a DNA polymerase.
  • the second temperature of a cycling step is approximately 57°C to 63°C, such as 59°C to 6PC, and the reaction is held at this temperature for a time period ranging between 0 seconds to 1 minute. This second temperature and time can vary greatly depending upon the primers (and probe(s), if present) and target polynucleotide used. This completes one cycling step. The next cycle then starts by raising the temperature of the reaction mixture to the denaturation temperature.
  • the cycle is repeated to provide the desired result, which may be to produce a quantity of DNA and/or detect an amplified product.
  • the number of cycling steps will depend, e.g., on the nature of the sample. If the sample is a complex mixture of polynucleotides, more cycling steps may be required to amplify the target polynucleotide sufficient for detection. Generally, the cycling steps are repeated at least about 20 times, but may be repeated as many as 40,
  • each cycle comprises detecting the product. Examples of detection methods are known in the art and some are discussed in more detail below. As will be understood by the skilled artisan, the above description of the thermal cycling reaction is provided for illustration only, and accordingly, the temperatures, times and cycle number can vary depending upon the nature of the thermal cycling reaction and application.
  • a third temperature is also used in a cycling step.
  • the use of three target temperatures also results in denaturation, annealing, and extension, but separate target temperatures are used for the denaturation, annealing, and extension.
  • the annealing temperatures generally range from 45°C to
  • the third target temperature is for extension, is typically held for a time period ranging between 30 seconds to 10 minutes, and occurs at a temperature range between the annealing and denaturing temperatures (e.g., generally between 68 and 72 degrees C).
  • a person skilled in the art will recognize that several factors, such as the primer annealing temperature, salt concentration, the overall complementarity between the primers and the target polynucleotide, and, in particular, the complementarity between the nucleotides proximal the 3' end of the primer and the corresponding nucleotides in the target polynucleotide.
  • DNA polymerases for use in the methods and compositions of the present invention are capable of effecting extension of a primer according to the methods of the present invention.
  • a preferred polymerase is one that is capable of extending a primer along a target polynucleotide.
  • a polymerase is thermostable.
  • a thermostable polymerase is a polymerase that is heat stable, i.e., the polymerase catalyzes the formation of primer extension products complementary to a template and does not irreversibly denature when subjected to the elevated temperatures for the time necessary to effect denaturation of double-stranded template nucleic acids.
  • Useful thermostable polymerases are well known and used routinely.
  • Thermostable polymerases have been isolated from Thermusflavus, T. ruber, T. thermophilus, T. aquaticus, T. lacteus, T. rubens, Bacillus stearothermophilus, and Methanothermus fervidus .
  • a polymerase typically initiates synthesis at the 3 '-end of a primer annealed to a target polynucleotide, and proceeds in the 5'-direction along the target polynucleotide.
  • a polymerase may possess a 5' to 3' exonuc lease activity, and hydro lyze intervening, annealed probe(s), if present, to release portions of the probe(s), until synthesis terminates.
  • suitable polymerases having a 5' to 3' exonuclease activity include, for example, Tf ⁇ , Taq, and FastStart Taq (Roche).
  • the polymerase has little or no 5' to 3' exonuclease activity so as to minimize degradation of primer, termination or primer extension polynucleotides.
  • This exonuclease activity may be dependent on factors such as pH, salt concentration, whether the target is double stranded or single stranded, and so forth, all of which are familiar to one skilled in the art.
  • suitable polymerases having little or no 5' to 3' exonuclease activity include Klentaq (Sigma, St. Louis, MO).
  • amplification involves mixing one or more target polynucleotides which can have different sequences with a "master mix" containing the reaction components for performing the amplification reaction and subjecting this reaction mixture to temperature conditions that allow for the amplification of the target polynucleotide.
  • the reaction components in the master mix can include a buffer which regulates the pH of the reaction mixture, magnesium ion, one or more of the natural nucleotides (corresponding to adenine, cytosine, guanine, and thymine or uracil, often present in equal concentrations), that provide the energy and nucleosides necessary for the synthesis of an amplification product, primer pairs that bind to the target in order to facilitate the initiation of polynucleotide synthesis, a polymerase that adds the nucleotides to the complementary strand being synthesized, and optionally, one or more probes.
  • a buffer which regulates the pH of the reaction mixture, magnesium ion, one or more of the natural nucleotides (corresponding to adenine, cytosine, guanine, and thymine or uracil, often present in equal concentrations), that provide the energy and nucleosides necessary for the synthesis of an amplification product, primer pairs that bind to the target in
  • a successful amplification reaction will not occur in the absence of a target polynucleotide, although the presence of a target polynucleotide is not required to perform the present methods.
  • the presence or absence of an amplified product can be determined or its amount measured.
  • Detecting an amplified product can be conducted by standard methods well known in the art and used routinely. The detecting may occur, for instance, after multiple amplification cycles have been run, or during each amplification cycle (typically referred to as real-time). Detecting an amplification product after multiple amplification cycles have been run is easily accomplished by, for instance, resolving the amplification product on a gel and determining whether the expected amplification product is present.
  • one or more of the primers used in the amplification reaction can be labeled, and various formats are available for generating a detectable signal that indicates an amplification product is present.
  • the most convenient label is typically fluorescent, which may be used in various formats including, but are not limited to, the use of donor fluorophore labels, acceptor fluorophore labels, fluorophores, quenchers, and combinations thereof.
  • the types of assays using the various formats may include the use of one or more primers that are labeled (for instance, scorpions primers, amplifluor primers). The skilled person will understand that in addition to these known formats, new types of formats are routinely disclosed.
  • the present invention is not limited by the type of method or the types of primers used to detect an amplified product. Using appropriate labels (for example, different fluorophores) it is possible to combine (multiplex) the results of several different primer pairs in a single reaction.
  • an amplification product can be detected using a polynucleotide binding dye such as a fluorescent DNA binding dye.
  • a polynucleotide binding dye such as a fluorescent DNA binding dye. Examples include, for instance, SYBRGreen or SYBRGoId (Molecular Probes).
  • SYBRGreen or SYBRGoId Molecular Probes
  • a polynucleotide binding dye such as a polynucleotide intercalating dye also can be used.
  • the present invention may be coupled with detection systems and methods involving separation and detection of the amplification products, such as the methods and detection system components described in PCT/IB2007/000923, filed on April 10, 2007, entitled NUCLEIC ACID DETECTION USING LATERAL FLOW METHODS, and in PCT Publication No. WO 2008/032205.
  • the first and second primer sequences are labelled with first and second labels, respectively.
  • the first and second labels are selected from haptens such as, for example, biotin, fluorescein derivatives (e.g. FITC), rhodamine derivatives (e.g.
  • the first label may be biotin and the second label may be DNP, in which case, amplicons generated during the amplification step are labelled with both biotin and DNP.
  • the primers are labelled with labelled deoxyribonucleotide triphosphates (dNTPs) such as, for example, labelled 2'-deoxyadenosine 5'-triphosphate (dATPs) and/or labelled T- deoxythymidine triphosphate (dTTPs).
  • dNTPs deoxyribonucleotide triphosphates
  • the amplicons can be captured on solid surfaces (e.g. chromatographic substrates, such as membranes, or microparticles) by, for example, antibodies, antibody fragments, receptors, or other binding partners, and detected using a system appropriate for the labels that are incorporated in the primers.
  • Detection system components include devices for capturing and detecting the amplicons, such as lateral flow devices and flow-through devices.
  • Microparticles are preferably composed of one or more substantially inert substances such as gold, silica, selenium, polystyrene, melamine resin, polymethacrylate, styrene/divinylbenzene copolymer, and polyvinyltoluene.
  • the microparticles are preferably non-porous.
  • the microparticles may comprise a substance to allow for visualisation of results at the test and control regions of the substrate.
  • such a substance will be a dye or other colored substance to allow for visualisation with the unaided eye
  • the substance may be, for example, a label substance allowing visualisation through the generation of a coloured substance (eg an enzyme or other catalytic-label) or by fluorescence, luminescence or magnetic interactions (e.g. using a fluorimeter, luminometer or magnetic induction).
  • the microparticles may be of a diameter size in the range of 0.002 to 5 ⁇ m.
  • the microparticles are gold microparticles having a diameter size in the range of 0.002 to 0.25 ⁇ m (i.e., 2 to 250 nm), more preferably 0.01 to 0.06 ⁇ m (ie 10 to 60 nm), and most preferably having an average diameter size of 0.04 ⁇ m (ie 40 nm).
  • Suitable polystyrene microparticles include those having a diameter size in the range of 0.1 to 5 ⁇ m. Controls can be included when an amplification reaction is run. Control target polynucleotides can be amplified from a positive control sample (e.g., a target polynucleotide other than mms) using, for example, control primers.
  • Positive control samples can also be used to amplify a target mms polynucleotide.
  • a control can be amplified internally (e.g., within each amplification reaction) or in separate samples run side -by-side with a subject's sample. Each run may also include a negative control that, for example, lacks a target mms.
  • suitable devices may include conventional amplification devices such as, for instance, the
  • Microfluidic refers to a device with one or more fluid passages, chambers, or conduits that have at least one internal cross-sectional dimension, e.g., depth, width, length, diameter, etc., that is less than 500 ⁇ m, and typically between 0.1 ⁇ m and 500 ⁇ m.
  • a microfluidic device typically includes a plurality of chambers (e.g., amplification reaction chambers, loading chambers, and the like), each of the chambers defining a volume for containing a sample.
  • chambers e.g., amplification reaction chambers, loading chambers, and the like
  • each of the chambers defining a volume for containing a sample.
  • the present invention also includes methods for isolating, preferably, purifying a polynucleotide.
  • the methods of this aspect of the present invention typically include providing a mixture that contains single stranded polynucleotides, exposing the mixture to an oligonucleotide of the present invention under suitable conditions for specific hybridization of the oligonucleotide to a single stranded polynucleotide to result in a hybrid, and isolating the hybrid from non- hybridized single stranded polynucleotides.
  • Such methods may be used to prepare a sample prior to amplification of a target polynucleotide present in E. sakazakii.
  • the method further comprises attaching the oligonucleotide to a solid phase material, such as a membrane or a microparticle.
  • the mixture may be obtained from a sample, preferably, a biological sample.
  • the sample may contain E. sakazakii.
  • the sample may be any suitable sample including, for example, a food sample, a sample prepared from a swab of a food preparation surface, a waste or process water sample, and a micro-organism culture or enrichment sample (e.g. a sample aliquot from the first or third tubes of a test or system sold by 3M Tecra under the tradenames UNIQUE, or IMMUNOCAPTURE, from a colony obtained from the surface of an agar plate or culture device sold by 3M
  • a micro-organism culture or enrichment sample e.g. a sample aliquot from the first or third tubes of a test or system sold by 3M Tecra under the tradenames UNIQUE, or IMMUNOCAPTURE, from a colony obtained from the surface of an agar plate or culture device sold by 3M
  • the sample may be prepared for isolation by extraction as described hereinabove.
  • the polynucleotides in the mixture may be impure (e.g., other cellular materials and/or solid debris are present), partially pure, or purified.
  • the polynucleotides in the mixture may be denatured using well known and routine methods. Examples of such methods include, for instance, heating, or exposure to alkaline conditions.
  • the mixture of single stranded polynucleotides is exposed to an oligonucleotide of the present invention in suitable conditions for specific hybridization of the oligonucleotide and the complementary single stranded polynucleotide.
  • the oligonucleotide typically includes a label, preferably an affinity label.
  • Conventional hybridization formats which are particularly useful include those where oligonucleotide is immobilized on a solid support (solid-phase hybridization) and those where the polynucleotides, (both single stranded polynucleotides and oligonucleotides) are all in solution (solution hybridization).
  • the oligonucleotide In solid-phase hybridization formats, the oligonucleotide is typically attached to a solid phase material prior to the hybridization. In solution hybridization formats, the oligonucleotide is typically attached to a solid phase material after the hybridization. In both formats, the attachment is mediated by a label, preferably an affinity label, that is attached to the oligonucleotide.
  • useful solid phase materials include, for instance, polyolefm, polystyrene, nylon, poly(meth)acrylate, polyacrylamide, polysaccharide, and fluorinated polymers, as well as resins such as agarose, latex, cellulose, and dextran.
  • the solid material may be in any form, preferably in the form of particulate material (e.g., particles, beads, microbeads, microspheres) or any other form (e.g., fibrils) that can be introduced into a microfluidic device (Parthasarathy, U.S. Provisional Application Serial Number 60/913,813, filed April 25, 2007, Attorney Docket No. 62470US002).
  • particulate material e.g., particles, beads, microbeads, microspheres
  • fibrils e.g., fibrils
  • the hybridization is performed under suitable conditions for selectively binding the labeled oligonucleotide to the substantially complementary, preferably complementary, single stranded polynucleotides present in the mixture, e.g., stringent hybridization conditions.
  • suitable conditions for selectively binding the labeled oligonucleotide to the substantially complementary, preferably complementary, single stranded polynucleotides present in the mixture e.g., stringent hybridization conditions.
  • suitable conditions for selectively binding the labeled oligonucleotide to the substantially complementary, preferably complementary, single stranded polynucleotides present in the mixture e.g., stringent hybridization conditions.
  • the hybridization conditions include the use of a hybridization buffer such as 6x SSC, 5x Denhardt's reagent, 0.5% [w/v] SDS, and a blocking reagent such as 100 ⁇ g/ml salmon sperm.
  • Hybridization may be allowed to occur at 68
  • the non- hybridized polynucleotides, and any other materials that may be present can be removed by washing at room temperature several times in a solution containing 2x SSC and 0.5% SDS.
  • the isolated polynucleotide may be purified by denaturing the hybrid to release the isolated polypeptide and removing the bound oligonucleotide and solid support.
  • kits which can include oligonucleotides of the present invention, such as, for instance, a primer pair, and optionally, a probe.
  • Other components that can be included within kits of the present invention include conventional reagents such as a master mix; hybridization solutions; detection system components such as solid phase supports (e.g., a membrane, a microparticle), flow- through devices, lateral flow devices,and external positive or negative controls; and the like.
  • kits typically include packaging material, which refers to one or more physical structures used to house the contents of the kit.
  • the packaging material can be constructed by well-known methods, preferably to provide a contaminant-free environment.
  • the packaging material may have a marking that indicates the contents of the kit.
  • the kit contains instructions indicating how the materials within the kit are employed.
  • packaging refers to a solid matrix or material such as glass, plastic, paper, foil, and the like.
  • Instructions typically include a tangible expression describing the various methods of the present invention, including sample preparation conditions, amplification conditions, and the like.
  • Primers were selected to enable PCR amplification of a region of E. sakazakii.
  • the primers selectively amplify a 50 bp region of the macromolecular synthesis (MMS) operon (see Genbank accession number LO 1755 for partial sequence).
  • MMS macromolecular synthesis
  • SEQ ID NO:1 and SEQ ID NO:2 correspond to the forward and reverse primers, respectively, in the PCR amplification reaction.
  • SEQ ID NO:3 corresponds to the nucleotide sequence disclosed in Genbank accession number L01755 .
  • SEQ ID NO: 1 corresponds to nucleotides 186-208 in SEQ ID NO:3
  • ACTACTACTC TGTCTGTTTC AGGGG corresponds to the complement of nucleotides 211-235 in
  • SEQ ID NO:3 181 CGTCTGT ACT AATTCCTCAG GGGATATTGT 211 CCCCTGAAAC AGACAGAGTA GTAGTTGTAG 241 AGGCCGTGCT TCCGAAAGGA ATGCGCGGCT 271 TATTCTCGTT TATGGGCTGA TAAAAACGGG 301 GCTTATGGCT GGACGAATC
  • the forward primer (SEQ ID NO: 1) was labelled at the 5' end with biotin and the reverse primer (SEQ ID NO:2) was labelled at the 5' end with fluorescein.
  • the labelled primers were obtained from Gene Works (Hindmarsh SA, Australia).
  • the detection membrane was prepared using nitrocellulose membrane (BA-83, Whatman).
  • Test anti-FITC antibody catalog number F5636, Sigma, MO, USA
  • Striping Solution Millenia Dignostics, CA, USA
  • approximately one microliter (per test unit) was applied in stripe format across the nitrocellulose membrane using a Bio Jet Quanti (BioDot, Irvine CA, USA) dispenser.
  • the membrane was dried at room temperature, blocked for one hour at room temperture using Lateral flow Blocking Buffer (Millenia Diagnostics, CA, USA), dried at room temperature and stored until use.
  • the membranes Prior to use, the membranes were cut to size (approximately 1.2 cm wide and 1.8 cm long) and used to assemble a detection cassette containing an absorbent pad (Pall-197, Pall, NY, USA) with a 0.8 cm diameter aperture as described in PCT Publication No. WO 2008/032205.
  • the side containing striped antibody faced the aperture of the cassette.
  • PCR amplification was conducted as follows using the primers described above (ie having the nucleotide sequences of SEQ ID NO: 1 and 2):
  • Dried PCR mix e.g. Bioneer Accupower, Korea
  • thermocycler Using a Mastercycler Personal (Eppendorf, Germany) thermocycler the inoculated PCR mix was subjected to an initial heating step of 94 0 C for 4 minutes; followed by
  • PBS phosphate buffered saline
  • the bacterial strains used in this example are listed in Table 2.
  • E. sakazakii and non-ii. sakazakii strains were grown overnight in TSB at 37 0 C.
  • Glycerol was added to each cell suspension to a final concentration of 25% (v/v) and the suspensions were stored frozen at -8O 0 C until they were used in the experiments.
  • TICC Tecra International Culture Collection
  • PCR primers Polymerase chain reaction (PCR) primers were prepared as described in
  • Example 1 The labeled and desalted primers were obtained from Geneworks (Hindmarsh SA, Australia). The forward primer (SEQ ID NO: 1) was labeled at the 5' end with biotin while the reverse primer (SEQ ID NO:2) was labeled at the 5' end with FITC. PCR amplification with these primers produced an amplicon of 50 nucleotides in length.
  • a lateral flow device was prepared using a strip of nitrocellulose membrane (Immunopore FP, Whatman) of approximately 5 mm x 60 mm in dimensions.
  • a sample pad (Arista Biologicals, Allentown, PA, USA) was applied to the strip to allow loading of the buffered assay sample.
  • an absorbent pad comprising cotton fibre (Arista Biochemicals, Allentown, PA, USA) was adhered to draw the flow of the buffered assay sample across the membrane.
  • the test line was prepared by adsorbing 0.46 ⁇ g anti-FITC monoclonal antibodies (Sigma-Aldrich, St. Louis, MO, USA) to the membrane in a thin line across the width of the membrane.
  • the entire lateral flow device was constructed by applying the membrane and sample and absorbent pads onto an adhesive backing card (Millenia Diagnostics, San Diego, CA, USA). Amplif ⁇ cation
  • PCR amplification was conducted in accordance with methods well known to persons skilled in the art, as described below. With the primers described above (i.e. SEQ ID NO: 1 and 2), the PCR amplification was conducted as follows: (i) Dried PCR mix (Accupower, Bioneer, Korea) was rehydrated using
  • PBS phosphate buffered saline
  • Tween-20 0.05%).
  • the buffered assay sample comprising the entire 115 ⁇ l aliquot of the buffered PCR product/gold microparticle mixture, was loaded onto the sample pad of the lateral flow device as described above. The constituents of the mixture were allowed to flow across the membrane for 5 minutes.
  • the test line comprising anti-FITC antibodies "trapped" doubly labeled amplicons present in the mixture that were labeled with FITC. Doubly labeled amplicons were bound to gold microparticles, and thus, when trapped at the test line by anti-FITC antibodies, generated a pinkish-red line.
  • E. sakazakii strains were readily detected by the presence of a pinkish-red line using the labeled primers and lateral flow detection method. Strains that should have been excluded from detection (i.e, all strains unrelated to E. sakazakii) did not display a pinkish-red line in the test region thereby indicating that the primers were specific for E. sakazakii and did not amplify the selected non-E. sakazakii strains.
  • One strain, known to display some characteristics of E. sakazakii (TICC # 2798, Enterobacter sp. amnigenus cloacae sakazakii) was detected using these primers indicating that this organism has a mms operon sequence complementary to the described primers .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés et des oligonucléotides permettant la détection d'Enterobacter sakazakii dans un échantillon, la séquence cible spécifique se trouvant dans l'opéron mms.
PCT/US2008/075663 2007-09-12 2008-09-09 Procédés de détection d'enterobacter sakazakii Ceased WO2009035955A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97168007P 2007-09-12 2007-09-12
US60/971,680 2007-09-12

Publications (1)

Publication Number Publication Date
WO2009035955A1 true WO2009035955A1 (fr) 2009-03-19

Family

ID=39855224

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/075663 Ceased WO2009035955A1 (fr) 2007-09-12 2008-09-09 Procédés de détection d'enterobacter sakazakii

Country Status (1)

Country Link
WO (1) WO2009035955A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011015356A1 (fr) * 2009-08-07 2011-02-10 Biotecon Diagnostics Gmbh Acides nucléiques et procédés pour la détection d'enterobacter sakazakii (cronobacter spp.)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006651A2 (fr) * 2000-07-18 2002-01-24 Siemens Aktiengesellschaft Appareil de commande pour automobile, muni d'un contacteur de pression
US20030104410A1 (en) * 2001-03-16 2003-06-05 Affymetrix, Inc. Human microarray
WO2004104550A2 (fr) * 2003-05-16 2004-12-02 Qualicon Incorporated Detection rapide et specifique enterobacter sakazakii
WO2008032205A2 (fr) * 2006-09-12 2008-03-20 3M Innovative Properties Company Détection d'acides nucléiques par des procédés en flux continu

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006651A2 (fr) * 2000-07-18 2002-01-24 Siemens Aktiengesellschaft Appareil de commande pour automobile, muni d'un contacteur de pression
US20030104410A1 (en) * 2001-03-16 2003-06-05 Affymetrix, Inc. Human microarray
WO2004104550A2 (fr) * 2003-05-16 2004-12-02 Qualicon Incorporated Detection rapide et specifique enterobacter sakazakii
WO2008032205A2 (fr) * 2006-09-12 2008-03-20 3M Innovative Properties Company Détection d'acides nucléiques par des procédés en flux continu

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 17 July 2003 (2003-07-17), "Sequence 6368 from Patent WO02066501.", XP002501146, retrieved from EBI accession no. EMBL:AX793904 Database accession no. AX793904 *
DATABASE Geneseq [online] 14 October 2003 (2003-10-14), "Human microarray DNA oligonucleotide SEQ ID NO 70162.", XP002501147, retrieved from EBI accession no. GSN:ACI70171 Database accession no. ACI70171 *
MOUILLESSEAUX KEVIN P ET AL: "Improvement in the specificity and sensitivity of detection for the Taura syndrome virus and yellow head virus of penaeid shrimp by increasing the amplicon size in SYBR Green real-time RT-PCR", JOURNAL OF VIROLOGICAL METHODS, ELSEVIER BV, NL, vol. 111, no. 2, 1 August 2003 (2003-08-01), pages 121 - 127, XP002461528, ISSN: 0166-0934 *
NAZAROWEC-WHITE M ET AL: "Enterobacter sakazakii: a review.", INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY FEB 1997, vol. 34, no. 2, February 1997 (1997-02-01), pages 103 - 113, XP002501145, ISSN: 0168-1605 *
SEO K H ET AL: "Rapid, specific detection of Enterobacter sakazakii in infant formula using a real-time PCR assay.", JOURNAL OF FOOD PROTECTION JAN 2005, vol. 68, no. 1, January 2005 (2005-01-01), pages 59 - 63, XP009107590, ISSN: 0362-028X *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011015356A1 (fr) * 2009-08-07 2011-02-10 Biotecon Diagnostics Gmbh Acides nucléiques et procédés pour la détection d'enterobacter sakazakii (cronobacter spp.)
EP2287333A1 (fr) * 2009-08-07 2011-02-23 Biotecon Diagnostics GmbH Acides nucléiques et procédés pour la détection d'enterobacter sakazakii (cronobacter spp.)
US11479826B2 (en) 2009-08-07 2022-10-25 Biotecon Diagnostics Gmbh Nucleic acids and methods for the detection of Enterobacter sakazakii (Cronobacter spp.)

Similar Documents

Publication Publication Date Title
AU2008317152B2 (en) Bordetella detection assay
CN102066573A (zh) 用于扩增多个靶标的扩增子拯救多重聚合酶链式反应
US5942394A (en) Detection of protozoan parasites
US20090226895A1 (en) Method of detecting vibrio parahaemolyticus via real-time PCR-hybridization
US20100233717A1 (en) Methods for detecting toxigenic microbes
JP2014530011A (ja) Ｓｔｅｃ細菌の配列ならびに検出および特徴決定のためのそれらの使用
JP2001505781A (ja) レジオネラ・ニューモフィラを検出するための核酸プライマー及びプローブ
US20110189665A1 (en) Methods for detecting drug-resistant microbes
JP2009506782A (ja) 結核の診断のための核酸標的としてのｒｄ９およびｉｓ６１１０の使用、ならびにマルチプレックス−コンプライアントｉｓ６１１０およびｒｄ９標的の提供
WO2020205491A1 (fr) Séquences et leur utilisation pour la détection et la caractérisation du genre cronobacter
EP3438280B1 (fr) Procédé de détection d'hémoplasme
WO2009035955A1 (fr) Procédés de détection d'enterobacter sakazakii
EP2959012B1 (fr) Séquences et leur utilisation en vue de la détection et de la caractérisation du sérotype o157:h7 d'e. coli
JP4766878B2 (ja) ハイブリダイゼーションアッセイを使用する真正細菌群の検出、同定および識別
US20100092949A1 (en) Methods for detecting staphylococcus aureus
WO2009035954A1 (fr) Procédés de détection de listeria monocytogenes
CN101092645B (zh) 诊断性传染病致病原的新颖方法
JP6181660B2 (ja) 血中のストレプトコッカス・ニューモニエの検出
WO2024003260A1 (fr) Compositions et procédés de détection de sérovars de chlamydia trachomatis provoquant un lymphogranulome vénérien (lgv)
EP3822370A1 (fr) Procédé de détermination de la présence d'une souche hyper-virulente de clostridioides difficile du groupe b1/nap1/027 dans un échantillon
AU2015289612A1 (en) Sequences and their use for detection of Listeria monocytogenes
JP2008161170A (ja) 高感度なサルモネラ属菌検出用オリゴヌクレオチド、それを用いた検出方法および検出キット
WO2020051301A1 (fr) Séquences et leur utilisation pour la détection et la caractérisation de e. coli o157:h7
JPH11243953A (ja) クリプトスポリジウム・パルバムを検出するためのプライマｄｎａ及びこれを用いるクリプトスポリジウム・パルバムの検出方法
Amorim et al. Animal Tuberculosis: Diagnosis by PCR Amplification and Hybridization to an Mycobacterium tuberculosis Complex-Specific Probe

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08799336

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08799336

Country of ref document: EP

Kind code of ref document: A1